BioCentury
ARTICLE | Company News

CHMP backs Vectibix, Trajenta, Eurartesim

June 25, 2011 1:58 AM UTC

EMA's CHMP issued several positive opinions on Friday, including a reversal of a prior decision for Vectibix panitumumab from Amgen Inc. (NASDAQ:AMGN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). CHMP recommended expanding the label of the human mAb against EGFR to include the treatment of metastatic colorectal cancer in patients with wild-type K-Ras (KRAS) tumors. On Friday, Amgen was off $0.89 to $57.04. ...